Neurocrine Pays $165M to Bankroll Voyager’s Gene Therapy for Parkinson’s

The road to potential approval for Voyager Therapeutics’ experimental gene therapy for Parkinson’s disease got a bit longer, and more expensive, last year. So this morning the company cut a deal with Neurocrine Biosciences to bankroll the journey—and forfeit some of the financial upside for the product, known as VY-AADC.